Physician profile
Rena Mehta
NPI 1356590293
$5,458.26
in general payments reported to CMS, 2019-2025
36 companies · $34.66 in 2025
The $34.66 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,170 · 2021: $1,211 · 2022: $872 · 2023: $871 · 2024: $436 · 2025: $34.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,342.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $916.88 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.99 | 2019-2024 | Jardiance |
| Abbvie INC. | $704.89 | 2019-2024 | |
| Novo Nordisk INC | $589.62 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $421.22 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $262.23 | 2020-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $192.97 | 2019-2021 | |
| Abbott Laboratories | $191.66 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amgen INC. | $186.60 | 2019-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $142.99 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $140.94 | 2019-2021 | |
| Lilly USA, LLC | $129.55 | 2020-2023 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $98.19 | 2021-2023 | |
| Corcept Therapeutics | $94.13 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $81.42 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.74 | 2021-2022 | |
| Esperion Therapeutics, INC. | $54.16 | 2021 | |
| Eisai INC. | $43.77 | 2020 | |
| Astellas Pharma US INC | $41.13 | 2020 | |
| Qol Medical, LLC | $36.21 | 2022-2025 | Sucraid |
| Stryker Corporation | $35.66 | 2019 | |
| Allergan, INC. | $34.31 | 2019-2020 | |
| Axsome Therapeutics, INC. | $31.05 | 2023 | Sunosi |
| Tandem Diabetes Care, INC. | $25.96 | 2019 | |
| Almatica Pharma LLC | $24.04 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.44 | 2021 | |
| Pfizer INC. | $21.45 | 2021 | |
| Companion Medical, INC. | $21.14 | 2019 | |
| Insulet Corporation | $18.94 | 2020 | |
| Zealand Pharma US, INC. | $18.62 | 2020 | |
| Amneal Pharmaceuticals LLC | $18.00 | 2020 | |
| Gilead Sciences, INC. | $17.28 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.92 | 2023 | Quviviq |
| Medline Industries LP | $15.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.88 | 2022 | |
| Sanofi Pasteur INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rena Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.